We know that surgeons have shifted from using Integra’s IDRT to BTM and not returned. And while the entire market for dermal replacements is expanding, BTM uptake is in hyper growth mode, IDRT is not.
You spin the India entry as the company “concentrating” on that market at the expense of the larger US market when there is absolutely no evidence of this. Entry into India is competitor free, low cost, but with potentially high returns for that cost - in all kinds of ways besides direct sales revenue.
We know that surgeons have shifted from using Integra’s IDRT to...
-
- There are more pages in this discussion • 942 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.30 |
Change
0.000(0.00%) |
Mkt cap ! $1.587B | |||
| Open | High | Low | Value | Volume |
| $2.34 | $2.35 | $2.27 | $1.711M | 744.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 14000 | $2.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.30 | 13896 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| PNV (ASX) Chart |